Breakthrough Ketamine Therapy for PTSD & Depression – NRx Pharma
Investors and biotech innovators—NRx Pharmaceuticals (NASDAQ: NRXP) is pioneering preservative-free ketamine therapy to combat PTSD, depression, and the veteran suicide epidemic.
In this episode of New to The Street, Jonathan Javitt, CEO of NRx Pharmaceuticals, sits down with Douglas Anderson of Wall Street Capital Partners to discuss revolutionary mental health treatments rooted in neuroplasticity. Learn how a reimagined version of ketamine, once used in the Vietnam War, is now showing transformative potential for suicide prevention and treatment-resistant depression—especially among veterans.
Key discussion points include:
Development of preservative-free ketamine to replace the outdated, toxic generic supply
Introduction of NRX-101 (D-cycloserine)—a promising treatment for suicidal ideation and akathisia
How combining ketamine, transcranial magnetic stimulation (TMS), and hyperbaric oxygen therapy is achieving 90{d450b60efc35a2e17361b5d57bc194208ff1ac62c46bd45a026f4271e6a4dcc4}+ response rates
Plans for a nationwide rollout of integrated mental health clinics with a “give us a week, we’ll give you your life back” promise
Recent FDA progress on their ANDA (Abbreviated New Drug Application)
This game-changing approach is giving new hope to patients and redefining the biotech landscape.
🔹 Ticker Symbol: NRXP
🔹 Learn more: https://www.nrxpharma.com
🎙 Hosted by Douglas Anderson | Wall Street Capital Partners
📌 Tags
#NRxPharmaceuticals #NRXP #KetamineTherapy #MentalHealthInnovation #VeteranSuicide #BiotechInvesting #FDAApproval #Neuroplasticity #TMS #Dcycloserine #NewToTheStreet #BloombergTV #FoxBusiness #MentalHealthTreatment #WallStreetCapitalPartners #HyperbaricOxygen #PTSDRecovery #PreservativeFreeKetamine #SuicidePrevention
